BACKGROUND: Major psychiatric diseases such as schizophrenia and mood disorders have not been linked to a specific pathology, but their clinical features overlap with some aspects of the behavioral variant of frontotemporal lobar degeneration. Although the significance of pathological 43-kDa (transactivation response) DNA-binding protein (TDP-43) for frontotemporal lobar degeneration was appreciated only recently, the prevalence of TDP-43 pathology in patients with severe mental illness vs controls has not been systematically addressed. OBJECTIVE: To examine patients with chronic psychiatric diseases, mainly schizophrenia, for evidence of neurodegenerative TDP-43 pathology in comparison with controls. DESIGN: Prospective longitudinal clinical evaluation and retrospective medical record review, immunohistochemical identification of pathological TDP-43 in the central nervous system, and genotyping for gene alterations known to cause TDP-43 proteinopathies including the TDP-43 (TARDBP) and progranulin (GRN) genes. SETTING: University health system. PARTICIPANTS: One hundred fifty-one subjects including 91 patients with severe mental illness (mainly schizophrenia) and 60 controls. MAIN OUTCOME MEASURES: Clinical medical record review, neuronal and glial TDP-43 pathology, and TARDP and GRN genotyping status. RESULTS: Significant TDP-43 pathology in the amygdala/periamygdaloid region or the hippocampus/transentorhinal cortex was absent in both groups in subjects younger than 65 years but present in elderly subjects (29% [25 of 86] of the psychiatric patients and 29% [10 of 34] of control subjects). Twenty-three percent (8 of 35) of the positive cases showed significant TDP-43 pathology in extended brain scans. There were no evident differences between the 2 groups in the frequency, degree, or morphological pattern of TDP-43 pathology. The latter included (1) subpial and subependymal, (2) focal, or (3) diffuse lesions in deep brain parenchyma and (4) perivascular pathology. A new GRN variant of unknown significance (c.620T>C, p.Met207Thr) was found in 1 patient with schizophrenia with TDP-43 pathology. No known TARDBP mutations or other variants were found in any of the subjects studied herein. CONCLUSIONS: The similar findings of TDP-43 pathology in elderly patients with severe mental illness and controls suggest common age-dependent TDP-43 changes in limbic brain areas that may signify that these regions are affected early in the course of a cerebral TDP-43 multisystem proteinopathy. Finally, our data provide an age-related baseline for the development of whole-brain pathological TDP-43 evolution schemata.
BACKGROUND: Major psychiatric diseases such as schizophrenia and mood disorders have not been linked to a specific pathology, but their clinical features overlap with some aspects of the behavioral variant of frontotemporal lobar degeneration. Although the significance of pathological 43-kDa (transactivation response) DNA-binding protein (TDP-43) for frontotemporal lobar degeneration was appreciated only recently, the prevalence of TDP-43 pathology in patients with severe mental illness vs controls has not been systematically addressed. OBJECTIVE: To examine patients with chronic psychiatric diseases, mainly schizophrenia, for evidence of neurodegenerative TDP-43 pathology in comparison with controls. DESIGN: Prospective longitudinal clinical evaluation and retrospective medical record review, immunohistochemical identification of pathological TDP-43 in the central nervous system, and genotyping for gene alterations known to cause TDP-43proteinopathies including the TDP-43 (TARDBP) and progranulin (GRN) genes. SETTING: University health system. PARTICIPANTS: One hundred fifty-one subjects including 91 patients with severe mental illness (mainly schizophrenia) and 60 controls. MAIN OUTCOME MEASURES: Clinical medical record review, neuronal and glial TDP-43 pathology, and TARDP and GRN genotyping status. RESULTS: Significant TDP-43 pathology in the amygdala/periamygdaloid region or the hippocampus/transentorhinal cortex was absent in both groups in subjects younger than 65 years but present in elderly subjects (29% [25 of 86] of the psychiatricpatients and 29% [10 of 34] of control subjects). Twenty-three percent (8 of 35) of the positive cases showed significant TDP-43 pathology in extended brain scans. There were no evident differences between the 2 groups in the frequency, degree, or morphological pattern of TDP-43 pathology. The latter included (1) subpial and subependymal, (2) focal, or (3) diffuse lesions in deep brain parenchyma and (4) perivascular pathology. A new GRN variant of unknown significance (c.620T>C, p.Met207Thr) was found in 1 patient with schizophrenia with TDP-43 pathology. No known TARDBP mutations or other variants were found in any of the subjects studied herein. CONCLUSIONS: The similar findings of TDP-43 pathology in elderly patients with severe mental illness and controls suggest common age-dependent TDP-43 changes in limbic brain areas that may signify that these regions are affected early in the course of a cerebral TDP-43multisystem proteinopathy. Finally, our data provide an age-related baseline for the development of whole-brain pathological TDP-43 evolution schemata.
Authors: Chang-En Yu; Thomas D Bird; Lynn M Bekris; Thomas J Montine; James B Leverenz; Ellen Steinbart; Nichole M Galloway; Howard Feldman; Randall Woltjer; Carol A Miller; Elisabeth McCarty Wood; Murray Grossman; Leo McCluskey; Christopher M Clark; Manuela Neumann; Adrian Danek; Douglas R Galasko; Steven E Arnold; Alice Chen-Plotkin; Anna Karydas; Bruce L Miller; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg; Vivianna M Van Deerlin Journal: Arch Neurol Date: 2010-02
Authors: Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Manuela Neumann; Rosa Rademakers; Sigrun Roeber; Matt Baker; Hans A Kretzschmar; Ian R A Mackenzie Journal: Brain Date: 2009-08-11 Impact factor: 13.501
Authors: John L Robinson; Felix Geser; Maria M Corrada; Daniel J Berlau; Steven E Arnold; Virginia M-Y Lee; Claudia H Kawas; John Q Trojanowski Journal: Brain Date: 2011-11-26 Impact factor: 13.501
Authors: Felix Geser; Beth Stein; Michael Partain; Lauren B Elman; Leo F McCluskey; Sharon X Xie; Vivianna M Van Deerlin; Linda K Kwong; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2011-01-12 Impact factor: 17.088
Authors: F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel Journal: Prog Neurobiol Date: 2011-09-03 Impact factor: 11.685
Authors: Shunsuke Koga; Naomi Kouri; Ronald L Walton; Mark T W Ebbert; Keith A Josephs; Irene Litvan; Neill Graff-Radford; J Eric Ahlskog; Ryan J Uitti; Jay A van Gerpen; Bradley F Boeve; Adam Parks; Owen A Ross; Dennis W Dickson Journal: Acta Neuropathol Date: 2018-06-20 Impact factor: 17.088
Authors: Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson Journal: Acta Neuropathol Date: 2019-01-02 Impact factor: 17.088
Authors: Anil Varma V Vatsavayi; Julia Kofler; Mary Ann A Demichele-Sweet; Patrick S Murray; Oscar L Lopez; Robert A Sweet Journal: Int Psychogeriatr Date: 2014-03-04 Impact factor: 3.878
Authors: Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider Journal: Brain Date: 2016-11-01 Impact factor: 13.501